Coronary Artery Disease is a Predictor for New-Onset AF after Heart Attack
Show: Ask Dr. DeSilva
Douglas L. Packer, MD, FHRS
Heart Disease and Heart Attacks
A new study published in the July edition of Heart*Rhythm *shows that *coronary artery disease is an independent predictor for new-onset atrial fibrillation after acute myocardial infarction (MI) or heart attack.* Douglas L. Packer, MD, FHRS, the Immediate Past President of the Heart Rhythm Society, comes on the show to explain the implications of the study anmd how it can affect people with heart disease.
Dr. Douglas L. Packer is the Immediate Past President of the Heart Rhythm Society. He serves as a consultant in the Division of Cardiovascular Diseases, Director of the Heart Rhythm Services, and Director of the Translational Electrophysiology Research Laboratory at Mayo Clinic Rochester. Dr. Packer is recognized with the academic rank of Professor of Medicine and is internationally known in cardiac electrophysiology. Dr. Packer is active in several medical associations and has served on editorial boards for the HeartRhythm Journal, American Heart Journal, Journal of Cardiovascular Electrophysiology, and Journal of the American College of Cardiology. In addition, he has served on National Heart, Lung, and Blood Institute work groups on atrial fibrillation. His translational work focuses on the mechanisms and ablation of atrial fibrillation and other cardiac arrhythmias, and autologous fibroblast modulation of electrical impulse propagation in the heart. His clinical work investigates 4/5 dimensional integrated image-guided ablation, and the development of new energy sources for the modification of cardiac tissue. His work has been funded in part by private foundations, the American Heart Association, and the National Institutes of Health (NIH). The researcher holds two US patents and one European patent. An active teacher and mentor, lecturer on cardiac arrhythmias and writer or co-author of more than 175 publications, Dr. Packer has served on the executive committee of several NIH multicenter randomized clinical trials, including the MUSTT, SCD-HeFT, and HAT Trials. In addition, he is the International Principal Investigator of the NIH CABANA Pivotal Study and leads the consortium of centers directing the trial. Dr. Packer received a medical degree from the University of Utah and completed an internship, residency and fellowship at Duke University, where he was on staff before relocating to Mayo Clinic Rochester. His honors and awards include the Distinguished Service Award from Brigham Young University.
Dr. Derrick DeSilva
Dr. DeSilva Advertisement
Channel Player (the latest segments)
Upcoming Live Shows
Login / Register